Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q1 2011

Global Markets Direct, January 2011, Pages: 81

Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q1 2011', provides an overview of the Gastrointestinal Stromal Tumors (GIST) therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Stromal Tumors (GIST), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumors (GIST). 'Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Stromal Tumors (GIST).
- A review of the Gastrointestinal Stromal Tumors (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastrointestinal Stromal Tumors (GIST) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumors (GIST).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumors (GIST) pipeline depth and focus of Gastrointestinal Stromal Tumors (GIST) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumors (GIST) Overview
Therapeutics Development
An Overview of Pipeline Products for Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumors (GIST) Therapeutics under Development by Companies
Gastrointestinal Stromal Tumors (GIST) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Gastrointestinal Stromal Tumors (GIST) Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
Nektar Therapeutics
Micromet, Inc.
Infinity Pharmaceuticals, Inc.
Ambrilia Biopharma Inc.
Novartis AG
Pfizer Inc.
Exelixis, Inc.
Bayer AG
AEterna Zentaris Inc.
Oncolytics Biotech Inc.
Synta Pharmaceuticals Corp.
Supratek Pharma Inc.
Neotropix, Inc.
Deciphera Pharmaceuticals, LLC
Concordia Pharmaceuticals
AB Science
ViRexx Medical Corp.
AstraZeneca AB
Universities/Institutes Involved in Gastrointestinal Stromal Tumors (GIST) Therapeutics Development
Gastrointestinal Stromal Tumors (GIST) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
AB1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMN107 + STI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C2L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPI-504 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Regorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tasigna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Bevacizumab + Imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Paclitaxel + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dactinomycin + methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glivec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Leucovorin Calcium + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radiation therapy + fluorouracil + mitomycin C + cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ursodeoxycholic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Gastrointestinal Stromal Tumors (GIST) - Featured News
Mar 20, 2009: Oncolytics Biotech (ONCY) Collaborators Update Combination REOLYSIN and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN And Docetaxel Results at iSBTc Annual Meeting
Apr 25, 2008: AVEO Initiates Phase 1b Combination Trial Of AV-951 With FOLFOX6 In Patients With Advanced Colorectal And Other Gastrointestinal Cancers
Feb 25, 2008: Experts Seek Regulatory Relook At New Pfizer Drug
Feb 13, 2008: Pfizer's Sutent Causes Heart Failure In Some Study
Sep 17, 2007: Infinity And MedImmune Receive Orphan Drug Designation For IPI-504 For Treatment Of Gastroinstestinal Stromal Tumors
Nov 08, 2006: Phase I Data For Exelixis' Kit Inhibitor XL820 Presents At EORTC
May 03, 2006: Biogen Idec To Acquire Conforma Therapeutics
Jan 10, 2006: Infinity Initiates Phase I Clinical Trial Of IPI-504 For Patients With Gastrointestinal Stromal Tumors
Jul 25, 2005: Exelixis Initiates Phase I Clinical Trial For Anticancer Compound XL820
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Gastrointestinal Stromal Tumors (GIST), 2011
Products under Development for Gastrointestinal Stromal Tumors (GIST) – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
F. Hoffmann-La Roche Ltd., 2011
Biogen Idec Inc., 2011
Amgen Inc., 2011
Nektar Therapeutics, 2011
Micromet, Inc., 2011
Infinity Pharmaceuticals, Inc., 2011
Ambrilia Biopharma Inc., 2011
Novartis AG, 2011
Pfizer Inc., 2011
Exelixis, Inc., 2011
Bayer AG, 2011
AEterna Zentaris Inc., 2011
Oncolytics Biotech Inc., 2011
Synta Pharmaceuticals Corp., 2011
Supratek Pharma Inc., 2011
Neotropix, Inc., 2011
Deciphera Pharmaceuticals, LLC, 2011
Concordia Pharmaceuticals, 2011
AB Science, 2011
ViRexx Medical Corp., 2011
AstraZeneca AB, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumors (GIST), 2011
Products under Development for Gastrointestinal Stromal Tumors (GIST) – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Customers who bought this item also bought

• Global Gastrointestinal Disorders Drug Pipeline Capsule - 2012
• Other Gastrointestinal Disorders - Pipeline Review, H2 2012
• Gastrointestinal Bleeding - Pipeline Review, H2 2012
• Brain Tumor – Pipeline Review, H1 2013
• Bronchiolitis - Pipeline Review, H2 2012
• Global Gastrointestinal Stromal Tumor Epidemiology and Patient Flow Analysis - 2012
• Gastrointestinal Stromal Tumors (GIST) Global Clinical Trials Review, Q4, 2010
• Nausea - Pipeline Review, H2 2012
• Bronchitis - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012